Understanding and targeting the challenges in treating small cell lung cancer
Investigating and Targeting Replication Stress in Small Cell Lung Cancer
This study is looking at small cell lung cancer to understand why some types respond better to chemotherapy than others, focusing on a protein called SLFN11, with the hope of finding new ways to help patients whose cancer doesn’t respond to treatment.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10848843 on NIH RePORTER |
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of lung cancer that often relapses after initial treatment. The project aims to identify the molecular factors that influence how different SCLC subtypes respond to chemotherapy, particularly looking at the role of a specific protein called SLFN11. Additionally, the researchers will explore how various pathways related to replication stress affect the cancer's sensitivity to treatment. By integrating these findings, the goal is to develop new strategies to overcome treatment resistance in SCLC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with small cell lung cancer, particularly those who have experienced relapse after initial chemotherapy.
Not a fit: Patients with non-small cell lung cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting replication stress in other cancer types, suggesting that this approach may be effective for small cell lung cancer as well.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Huang, Tony Tung — New York University School of Medicine
- Study coordinator: Huang, Tony Tung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.